Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.83 |
| ▸ | CHRNA7 | P36544 | 14/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.55 |
| ▸ | HTR3B | O95264 | 1/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101753 | 0.91 | HTR3A (1.00) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1090596 | 0.90 | HTR3A (0.98) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL20131904 | 0.88 | HTR3A (0.80) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1459342 | 0.87 | HTR3A (0.76) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1101795 | 0.87 | HTR3A (0.76) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1091297 | 0.87 | HTR3A (0.75) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1101986 | 0.80 | HTR3A (0.78) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL1101748 | 0.80 | CHRNA7 (0.76) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1090845 | 0.79 | HTR3A (0.77) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL1091409 | 0.79 | CHRNA7 (0.74) | HTR3ACHRNA7HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | HTR3A 452/4885CHRNA7 1/4885HTR3E 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.